top of page

AI in Drug Discovery in Asia Platform

Asia is at the forefront of integrating AI into drug discovery, presenting a landscape rich in innovation. Our platform provides a comprehensive view tailored for scholars, industry professionals, investors, and other interested parties. AI in drug discovery in Asia incorporates information about more than 140 companies, backed by 350 investors, collaborating with 25 local R&D hubs. The platform also includes profiles of the top 30 industry leaders in Asia that are driving this transformative wave in the pharmaceutical sector.

Frame 1-7.png

Beta Version

Leaders in AI for Drug Discovery in Asia

Leading the way in the field of AI in drug discovery in Asia are a diverse group of experts driving innovation. This group consists of researchers, data scientists, endocrinologists, and technologists who are committed to harnessing the potential of AI to tackle the complex challenges of drug discovery in Asia management. Their specialized knowledge and collaborative efforts are essential in developing state-of-the-art AI algorithms, predictive models, and decision support systems that enhance the delivery of drug discovery in Asia services.

AI in Drug Discovery in Asia Analytical Report

The main trends and technologies shaping the future of the industry today, distilling key insights for major industry participants and stakeholders

One Pager
Coming soon
Screenshot 2024-03-25 at 14.43.51.png
Coming soon

Global AI in Drug Discovery Landscape

Analytics platform to explore how AI is revolutionizing drug discovery globally. You will gain access to our interactive databases for AI in drug discovery, containing filterable, searchable, interactive mindmaps and profiles of 950 companies, 2,100 investors, 90 corporations, 50 hubs, and 100 leaders.

AI in DD 2024 New.png

Beta Version

AI in BioMed.png

Beta Version

AI in BioMed Platform

AI in BioMed is a comprehensive platform created to shed light on the developing nexus between artificial intelligence and biotechnology. Access to ground-breaking AI frameworks, powerful investors, business leaders, well-known organizations, and state-of-the-art research facilities are all available through this complex center, which addresses a range of subjects from biomarkers and drug discovery to neurotech and space medicine. AI in BioMed, which personifies the industry's future, acts as the unmistakable entryway to the insights and innovations that help to form and advance the sector.

Explore Solutions

Forecasting _ Predictions.jpg
Proprietary Analytics
Discover Dashboards Constructor™
Image by Alexandra Lee
Clinical Trials
Market Intelligence
Forecasting _ Predictions.jpg
Big Data Analytical System & Dashboards

Keen to Discover More?

To gain more insight into our solutions, schedule an introductory call with us.

Big Data Analytics Dashboard

Deep Pharma Intelligence has engineered an advanced analytical framework capable of defining, analysing, and predicting trends in the AI in Drug Development industry, and the DeepTech technologies powering it.

The Dashboard provides professional users with comparative analytical capabilities, including interactive, searchable and filterable databases of companies, investors and funding rounds, as well as Automated SWOT Analysis and AI-Driven Smart-Matching facilities.


Partnership with Deep Pharma Intelligence

Become a Partner and Drive Innovation in AI-Enabled Drug Discovery

Our Partners

Aging Analytics Agency (color + black).png
AI Industry Analytics (color).png

Strategic Partner Projects

Philanthropy International (1).png
Longevity International (1).png

Deep Pharma Intelligence – Powered by Deep Knowledge Group

Deep Pharma Intelligence is a subsidiary of Deep Knowledge Group, a data-driven consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, BioTech, Pharma, FinTech, GovTech, SpaceTech, FemTech, Data Science, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, consulting, media, philanthropy and more.

bottom of page